Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CFO Sells $370,755.00 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CFO Jeffrey V. Poulton sold 1,605 shares of the business’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $231.00, for a total transaction of $370,755.00. Following the completion of the transaction, the chief financial officer now owns 28,892 shares in the company, valued at $6,674,052. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Alnylam Pharmaceuticals Stock Down 1.6 %

Shares of ALNY stock opened at $243.00 on Friday. The company has a market capitalization of $30.74 billion, a price-to-earnings ratio of -90.67 and a beta of 0.30. The firm has a fifty day moving average of $159.86 and a 200-day moving average of $164.73. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $252.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. The business’s revenue was up 54.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.40) EPS. On average, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -3.75 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on ALNY shares. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. TD Cowen upped their target price on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a “buy” rating in a research report on Tuesday. Citigroup upped their target price on shares of Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the stock a “buy” rating in a research report on Tuesday. Chardan Capital reiterated a “buy” rating and set a $225.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, May 3rd. Finally, Evercore ISI increased their price objective on shares of Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday. Eight equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $247.09.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. ANTIPODES PARTNERS Ltd lifted its stake in shares of Alnylam Pharmaceuticals by 69.1% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 189,141 shares of the biopharmaceutical company’s stock worth $36,203,000 after buying an additional 77,307 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after buying an additional 287,064 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its stake in shares of Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 12,513 shares during the last quarter. Westpac Banking Corp lifted its stake in shares of Alnylam Pharmaceuticals by 59.8% during the 4th quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 566 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Alnylam Pharmaceuticals by 630.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,160 shares of the biopharmaceutical company’s stock worth $5,007,000 after buying an additional 22,580 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.